Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies
The endothelium, a cellular monolayer lining the blood vessel wall, plays a critical role in
maintaining multiorgan health and homeostasis. Endothelial functions in health include …
maintaining multiorgan health and homeostasis. Endothelial functions in health include …
Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review
GD Lopaschuk, S Verma - Basic to Translational Science, 2020 - jacc.org
Recent clinical trials have shown that sodium glucose co-transport 2 (SGLT2) inhibitors have
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …
dramatic beneficial cardiovascular outcomes. These include a reduced incidence of …
Direct cardiac effects of SGLT2 inhibitors
Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
[HTML][HTML] Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects
Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
F Bonnet, AJ Scheen - Diabetes & metabolism, 2018 - Elsevier
Chronic low-grade inflammation is a recognized key feature associated with type 2 diabetes
mellitus (T2DM) and its complications. In prospective randomized trials, sodium-glucose …
mellitus (T2DM) and its complications. In prospective randomized trials, sodium-glucose …
[HTML][HTML] Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …
Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients
L Uthman, A Baartscheer, CA Schumacher… - Frontiers in …, 2018 - frontiersin.org
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are the first antidiabetic compounds that
effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics …
effectively reduce heart failure hospitalization and cardiovascular death in type 2 diabetics …
Cardiovascular benefits from gliflozins: effects on endothelial function
T Salvatore, A Caturano, R Galiero, A Di Martino… - Biomedicines, 2021 - mdpi.com
Type 2 diabetes mellitus (T2DM) is a known independent risk factor for atherosclerotic
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …
[HTML][HTML] Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
K Urbanek, D Cappetta, G Bellocchio… - Pharmacological …, 2023 - Elsevier
Cardiorenal syndrome encompasses a spectrum of disorders involving heart and kidney
dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical …
dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical …
Reno-and cardioprotective molecular mechanisms of SGLT2 inhibitors beyond glycemic control: from bedside to bench
X Chen, CF Hocher, L Shen… - American Journal of …, 2023 - journals.physiology.org
Large placebo-controlled clinical trials have shown that sodium-glucose cotransporter-2
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …
inhibitors (SGLT2i) delay the deterioration of renal function and reduce cardiovascular …